In modern healthcare, biomarkers are an integral part of approaches to monitoring patient health and condition, providing researchers with a means of predicting treatment response. But what was the first biomarker to be discovered?

On-Demand Webinar featuring Dr Mo Jain, Founder & CEO of Sapient

This webinar shares how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data are being leveraged for robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.

While constraints on the integration of NGS approaches in selection biomarker validation for new treatments still need ironing out, their benefits in assisting clinical trial progress are undeniable.

With efforts already being made to apply artificial intelligence to imaging data for improved biomarker validation, AI is here to stay. However, to truly streamline drug development it needs to be implemented practically.

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.

Scientists at VCU Massey Cancer Center pinpoint druggable target in aggressive breast cancer.

Introducing PreciNASH, a multidisciplinary consortium strengthening the link between research outputs and clinical applications in NASH disease treatment.

From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.

Biomarkers come in many shapes and sizes. It’s an ever-evolving subject with many under-discovered possibilities. Let’s look at some ways biomarkers are looking to evolve.